Intensity Therapeutics Inc [NASDAQ: INTS] jumped around 0.03 points on Wednesday, while shares priced at $0.32 at the close of the session, up 11.58%.
Intensity Therapeutics Inc stock is now -81.87% down from its year-to-date (YTD) trading value. INTS Stock saw the intraday high of $0.3599 and lowest of $0.2813 per share. The company’s 52-week high price is 5.10, which means current price is +14.50% above from all time high which was touched on 01/16/25.
Compared to the average trading volume of 958.88K shares, INTS reached a trading volume of 4228861 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Intensity Therapeutics Inc [INTS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INTS shares is $5.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INTS stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Intensity Therapeutics Inc is set at 0.10 The Price to Book ratio for the last quarter was 14.58, with the Price to Cash per share for the same quarter was set at 0.05.
How has INTS stock performed recently?
Intensity Therapeutics Inc [INTS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -44.91. With this latest performance, INTS shares dropped by -20.47% in over the last four-week period, additionally sinking by -84.51% over the last 6 months – not to mention a drop of -93.45% in the past year of trading.
Intensity Therapeutics Inc [INTS]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -194.04%, with Return on Assets sitting at -194.04%.
Earnings analysis for Intensity Therapeutics Inc [INTS]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INTS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Intensity Therapeutics Inc go to 17.65%.
Insider trade positions for Intensity Therapeutics Inc [INTS]
There are presently around $9.99%, or 13.08%% of INTS stock, in the hands of institutional investors. The top three institutional holders of INTS stocks are: SAPIENT CAPITAL LLC with ownership of 1.01 million shares, which is approximately 7.3712%. VANGUARD GROUP INC, holding 0.2 million shares of the stock with an approximate value of $$1.0 million in INTS stocks shares; and VANGUARD GROUP INC, currently with $$0.77 million in INTS stock with ownership which is approximately 1.1488%.
